VV-IL-2

VV-IL-2 is a recombinant interleukin-2 (IL-2) drug candidate designed as an immunotherapy. Interleukin-2 is a cytokine and biologic response modifier that modulates the immune system, particularly by stimulating T cell and natural killer (NK) cell activity and promoting T regulatory (Treg) cell expansion[5][6]. VV-IL-2 is a modified version of IL-2 aimed at overcoming limitations of natural IL-2, such as short half-life and dose-limiting toxicities, with greater Treg selectivity and potentially improved pharmacokinetic properties[6]. Such second-generation IL-2 analogs, including VV-IL-2, are developed to treat cancer and autoimmune diseases, leveraging immunomodulatory mechanisms to enhance therapeutic benefit[6]. The precise nature of VV-IL-2’s modifications (such as PEGylation, mutein engineering, fusion proteins, or antibody complexes) is consistent with current industry approaches to advanced IL-2 therapeutics, though the explicit structure or modification of VV-IL-2 is not detailed in the provided results[6]. Its primary indications are expected to include oncology (solid tumors) and immune-mediated disorders.

Brand names

VV-IL-2VV-IL2VV-IL 2

Other names

VV-IL-2VV-IL2VV-IL 2